This study is testing a medication called Apremilast (60mg/day) to see if it can help adults with Alcohol Use Disorder (AUD). You would be randomly assigned to receive either Apremilast or a placebo (an inactive pill). Researchers will measure how much alcohol you drink during lab sessions and in your daily life. To join, you must be between 21 and 65 years old, able to read and write English, and meet specific drinking criteria for AUD. The study aims to enroll 80 participants. The current recruitment status is unclear.

Study design

This is a Phase 2, double-blind, placebo-controlled study, meaning neither you nor the study staff will know if you are receiving Apremilast or placebo. About 80 adults with Alcohol Use Disorder will participate.

What's involved

You would have an intake session and a physical exam. If eligible, you would take study medication for 28 days, including 6 days to reach a steady dose and three lab sessions. You will also be assessed for an additional month after stopping medication.

Compensation

Not stated in the trial record.

Follow-up

After stopping the study medication, you will be assessed for an additional one-month period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.